Table1_Immune-related adverse events in small-cell lung cancer patients treated with immune checkpoint inhibitors: a comprehensive analysis from the FDA adverse event reporting system.pdf
Background<p>The discovery and development of immune checkpoint inhibitors (ICIs) have resulted in their application as a novel therapeutic strategy for patients with small-cell lung cancer (SCLC). However, a comprehensive analysis of the potential adverse effects of ICIs in patients with SCLC...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , |
| منشور في: |
2024
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1852025563331428352 |
|---|---|
| author | Yifeng Bai (586123) |
| author2 | Xiaomei Wang (146367) Xiaoqin Dai (130507) Qinghua Ma (580671) Honglin Hu (3389774) |
| author2_role | author author author author |
| author_facet | Yifeng Bai (586123) Xiaomei Wang (146367) Xiaoqin Dai (130507) Qinghua Ma (580671) Honglin Hu (3389774) |
| author_role | author |
| dc.creator.none.fl_str_mv | Yifeng Bai (586123) Xiaomei Wang (146367) Xiaoqin Dai (130507) Qinghua Ma (580671) Honglin Hu (3389774) |
| dc.date.none.fl_str_mv | 2024-10-30T08:13:34Z |
| dc.identifier.none.fl_str_mv | 10.3389/fphar.2024.1398667.s001 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/dataset/Table1_Immune-related_adverse_events_in_small-cell_lung_cancer_patients_treated_with_immune_checkpoint_inhibitors_a_comprehensive_analysis_from_the_FDA_adverse_event_reporting_system_pdf/27330471 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Pharmacology Basic Pharmacology Clinical Pharmacology and Therapeutics Clinical Pharmacy and Pharmacy Practice Pharmaceutical Sciences Pharmacogenomics Toxicology (incl. Clinical Toxicology) Pharmacology and Pharmaceutical Sciences not elsewhere classified SCLC FDA adverse event reporting system (FAERS) ICIs immune check point inhibitors irAEs (immune-related adverse events) adverse (side) effects |
| dc.title.none.fl_str_mv | Table1_Immune-related adverse events in small-cell lung cancer patients treated with immune checkpoint inhibitors: a comprehensive analysis from the FDA adverse event reporting system.pdf |
| dc.type.none.fl_str_mv | Dataset info:eu-repo/semantics/publishedVersion dataset |
| description | Background<p>The discovery and development of immune checkpoint inhibitors (ICIs) have resulted in their application as a novel therapeutic strategy for patients with small-cell lung cancer (SCLC). However, a comprehensive analysis of the potential adverse effects of ICIs in patients with SCLC remains to be conducted.</p>Methods<p>Adverse event (ADE) reports relating to SCLC patients, submitted to the FDA Adverse Event Reporting System (FAERS) from the first quarter of 2013 to the second quarter of 2022, were extracted for analysis. The extracted data were subsequently screened and analyzed using the reporting odds ratio (ROR) method to assess the AE reports.</p>Results<p>A total of 4,522 ADE reports were obtained from patients with SCLC who had received either chemotherapy alone or a combination of ICIs with chemotherapy. The ROR analysis identified a total of 91 immune-related adverse events in SCLC patients associated with the ICIs (SCLC-irAEs).</p>Conclusion<p>This study revealed that the adverse effects resulting from irAEs in SCLC patients predominantly affected the hematologic and gastrointestinal systems, with the most severe cases potentially leading to fatality.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_06fc12b60db4bc4e85a1716884d20ff7 |
| identifier_str_mv | 10.3389/fphar.2024.1398667.s001 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/27330471 |
| publishDate | 2024 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Table1_Immune-related adverse events in small-cell lung cancer patients treated with immune checkpoint inhibitors: a comprehensive analysis from the FDA adverse event reporting system.pdfYifeng Bai (586123)Xiaomei Wang (146367)Xiaoqin Dai (130507)Qinghua Ma (580671)Honglin Hu (3389774)PharmacologyBasic PharmacologyClinical Pharmacology and TherapeuticsClinical Pharmacy and Pharmacy PracticePharmaceutical SciencesPharmacogenomicsToxicology (incl. Clinical Toxicology)Pharmacology and Pharmaceutical Sciences not elsewhere classifiedSCLCFDA adverse event reporting system (FAERS)ICIsimmune check point inhibitorsirAEs (immune-related adverse events)adverse (side) effectsBackground<p>The discovery and development of immune checkpoint inhibitors (ICIs) have resulted in their application as a novel therapeutic strategy for patients with small-cell lung cancer (SCLC). However, a comprehensive analysis of the potential adverse effects of ICIs in patients with SCLC remains to be conducted.</p>Methods<p>Adverse event (ADE) reports relating to SCLC patients, submitted to the FDA Adverse Event Reporting System (FAERS) from the first quarter of 2013 to the second quarter of 2022, were extracted for analysis. The extracted data were subsequently screened and analyzed using the reporting odds ratio (ROR) method to assess the AE reports.</p>Results<p>A total of 4,522 ADE reports were obtained from patients with SCLC who had received either chemotherapy alone or a combination of ICIs with chemotherapy. The ROR analysis identified a total of 91 immune-related adverse events in SCLC patients associated with the ICIs (SCLC-irAEs).</p>Conclusion<p>This study revealed that the adverse effects resulting from irAEs in SCLC patients predominantly affected the hematologic and gastrointestinal systems, with the most severe cases potentially leading to fatality.</p>2024-10-30T08:13:34ZDatasetinfo:eu-repo/semantics/publishedVersiondataset10.3389/fphar.2024.1398667.s001https://figshare.com/articles/dataset/Table1_Immune-related_adverse_events_in_small-cell_lung_cancer_patients_treated_with_immune_checkpoint_inhibitors_a_comprehensive_analysis_from_the_FDA_adverse_event_reporting_system_pdf/27330471CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/273304712024-10-30T08:13:34Z |
| spellingShingle | Table1_Immune-related adverse events in small-cell lung cancer patients treated with immune checkpoint inhibitors: a comprehensive analysis from the FDA adverse event reporting system.pdf Yifeng Bai (586123) Pharmacology Basic Pharmacology Clinical Pharmacology and Therapeutics Clinical Pharmacy and Pharmacy Practice Pharmaceutical Sciences Pharmacogenomics Toxicology (incl. Clinical Toxicology) Pharmacology and Pharmaceutical Sciences not elsewhere classified SCLC FDA adverse event reporting system (FAERS) ICIs immune check point inhibitors irAEs (immune-related adverse events) adverse (side) effects |
| status_str | publishedVersion |
| title | Table1_Immune-related adverse events in small-cell lung cancer patients treated with immune checkpoint inhibitors: a comprehensive analysis from the FDA adverse event reporting system.pdf |
| title_full | Table1_Immune-related adverse events in small-cell lung cancer patients treated with immune checkpoint inhibitors: a comprehensive analysis from the FDA adverse event reporting system.pdf |
| title_fullStr | Table1_Immune-related adverse events in small-cell lung cancer patients treated with immune checkpoint inhibitors: a comprehensive analysis from the FDA adverse event reporting system.pdf |
| title_full_unstemmed | Table1_Immune-related adverse events in small-cell lung cancer patients treated with immune checkpoint inhibitors: a comprehensive analysis from the FDA adverse event reporting system.pdf |
| title_short | Table1_Immune-related adverse events in small-cell lung cancer patients treated with immune checkpoint inhibitors: a comprehensive analysis from the FDA adverse event reporting system.pdf |
| title_sort | Table1_Immune-related adverse events in small-cell lung cancer patients treated with immune checkpoint inhibitors: a comprehensive analysis from the FDA adverse event reporting system.pdf |
| topic | Pharmacology Basic Pharmacology Clinical Pharmacology and Therapeutics Clinical Pharmacy and Pharmacy Practice Pharmaceutical Sciences Pharmacogenomics Toxicology (incl. Clinical Toxicology) Pharmacology and Pharmaceutical Sciences not elsewhere classified SCLC FDA adverse event reporting system (FAERS) ICIs immune check point inhibitors irAEs (immune-related adverse events) adverse (side) effects |